News for Genprex, Inc. (0A8I.L)

PR NewswireAUSTIN, Texas, June 3, 2025 AUSTIN, Texas, June 3, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-st

Genprex, Inc. (GNPX) to attend BIO 2025 International Convention in Boston from June 16-19, 2025. Thomas Gallagher, Senior VP of Intellectual Property and L

PR NewswireAUSTIN, Texas, May 29, 2025 Presentation to Highlight Genprex's Study of Reqorsa® Gene Therapy in Combination with Tecentriq® for the Treatmen

Genprex (GNPX) to present Acclaim-3 trial design at the 2025 ASCO Annual Meeting. The trial investigates Reqorsa® Gene Therapy combined with Tecentriq® to

WestPark Capital has taken on the role of the sole placement agent for GNPX. This move positions WestPark as a key player in the financial activities surroundin

PR NewswireAUSTIN, Texas, May 7, 2025 Advances Relationship and Collaboration with the University of Pittsburgh of the Commonwealth System of Higher Educat

Genprex, Inc. (GNPX) has announced a new Sponsored Research Agreement (SRA) with the University of Pittsburgh, extending their collaboration to explore the pote

PR NewswireAUSTIN, Texas, May 6, 2025 License Expands Genprex's Portfolio of Oncology Gene Therapy TechnologiesAUSTIN, Texas, May 6, 2025 /PRNewswire/ -- G

Genprex, symbolized by GNPX, has obtained an exclusive patent license agreement with UTHealth Houston. This agreement grants Genprex commercial rights for Reqor

Genprex's (GNPX) research team delivered encouraging preclinical results for its Reqorsa Gene Therapy targeting KRASG12C mutant non-small cell lung cancer (NSCL

PR NewswireAUSTIN, Texas, April 30, 2025 Both REQORSA Alone and in Combination with LUMAKRAS® Demonstrated Robust Anti-Tumor Effects in Ras Inhibitor Resi

PR NewswireAUSTIN, Texas, April 29, 2025 Novel Gene Therapy Program Offers a Promising Opportunity for Curative Therapy in DiabetesAUSTIN, Texas, April 29,

Genprex (GNPX) is set to present promising preclinical data on its diabetes gene therapy, GPX-002, at the ASGCT 28th Annual Meeting in May 2025. The the

PR NewswireAUSTIN, Texas, April 28, 2025 Additional Gene Therapy Technology Expands Genprex's Portfolio of Oncology LicensesAUSTIN, Texas, April 28, 2025 /

Shares of Penguin Solutions, Inc. PENG rose sharply in today's pre-market trading after the company posted better-than-expected results for its second quarter o...

PR NewswireAUSTIN, Texas, March 25, 2025 Novel Gene Therapy Program is Addressing Type 1 and Type 2 DiabetesAUSTIN, Texas, March 25, 2025 /PRNewswire/ -- G

Shares of Harrow, Inc. HROW rose sharply in pre-market trading after the company reported fourth quarter and year-end 2024 unaudited preliminary financial resul...

PR NewswireAUSTIN, Texas, March 4, 2025 AUSTIN, Texas, March 4, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-

PR NewswireAUSTIN, Texas, Feb. 18, 2025 Signs an Amended & Restated License Agreement for Multiple Technologies for Gene Therapy for Type 1 and Type 2 Diab